Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(03): 316-320
DOI: 10.4103/ijmpo.ijmpo_107_17
Original Article

Clinicopathological Features and Treatment Outcomes in Ewing’s Sarcoma Patients: A 10‑year experience of Alexandria Clinical Oncology Department

Asmaa Nazeer
Department of Oncology, Alexandria Sporting Students' Hospital, Alexandria, Egypt
,
Alaa Kandil
Department of Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Omar Zahra
Department of Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Maher Soliman
Department of Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Ewing's sarcoma (ES) is an aggressive tumor, which is usually associated with micrometastases in the circulation. Thus, systemic chemotherapy in addition to local control modality is essential to improve outcomes. The aim of this study was to evaluate clinicopathological features and treatment outcomes in patients with ES. Materials and Methods: Medical files of 74 patients with nonmetastatic ES treated at our centers between 2004 and 2014 were retrospectively evaluated. The clinicopathological parameters were extracted and statistically correlated with event-free survival (EFS) and overall survival (OS). Results: The median age of patients was 13 years. The median follow-up duration was 63.8 months. About two-thirds (58.1%) of patients were male. Pain (74.3%) was the most common presenting symptom. Extremities (48.6%) were the frequently affected sites. Thirty-two patients (43.2%) presented by tumors larger than 8 cm. All patients were treated with chemotherapy. Local therapies were surgery and/or radiotherapy. The 5-year EFS and OS were 44% and 57%, respectively. On multivariate analysis, EFS and OS were significantly associated with age, tumor site, and tumor size. Conclusions: Despite limited resources in a developing country, the survival rates of ES are comparable to that in developed countries, and prognostic factors are age, tumor site, and tumor size.

Keywords

Chemotherapy - Ewing's sarcoma - prognosis - survival


Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Siegel DA, King J, Tai E, Buchanan N, Ajani UA, Li J. Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009. Pediatrics 2014;134:e945-55.
  • 2 Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010;116:443-50.
  • 3 Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al. Long-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study. J Natl Cancer Inst 2010;102:1272-83.
  • 4 Jürgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988;61:23-32.
  • 5 Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
  • 6 Burgert EO Jr. Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 1990;8:1514-24.
  • 7 Rodríguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital Studies. Cancer 2007;110:375-84.
  • 8 Biswas B, Rastogi S, Khan SA, Mohanti BK, Sharma DN, Sharma MC, et al. Outcomes and prognostic factors for Ewing-family tumors of the extremities. J Bone Joint Surg Am 2014;96:841-9.
  • 9 Tural D, Molinas Mandel N, Dervisoglu S, Oner Dincbas F, Koca S, Colpan Oksuz D, et al. Extraskeletal Ewing's sarcoma family of tumors in adults: Prognostic factors and clinical outcome. Jpn J Clin Oncol 2012;42:420-6.
  • 10 Arpaci E, Yetisyigit T, Seker M, Uncu D, Uyeturk U, Oksuzoglu B, et al. Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: Multicentric study of the Anatolian Society of Medical Oncology. Med Oncol 2013;30:469.
  • 11 Abou Ali B, Nader R, Tamim H, Eid T, Boulos F, Khoury N, et al. Outcome of Ewing sarcoma in a multidisciplinary setting in Lebanon. Pediatr Blood Cancer 2014;61:1472-5.
  • 12 Akhavan A, Binesh F, Shamshiri H, Ghanadi F. Survival of patients with Ewing's sarcoma in Yazd-Iran. Asian Pac J Cancer Prev 2014;15:4861-4.
  • 13 Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: Final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001;19:1818-29.
  • 14 Obata H, Ueda T, Kawai A, Ishii T, Ozaki T, Abe S, et al. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: The Japanese Musculoskeletal Oncology Group cooperative study. Cancer 2007;109:767-75.
  • 15 Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000;82:667-74.
  • 16 Oksüz DC, Tural D, Dincbas FÖ, Dervisoglu S, Turna H, Hiz M, et al. Non-metastatic Ewing's sarcoma family of tumors of bone in adolescents and adults: Prognostic factors and clinical outcome-single institution results. Tumori 2014;100:452-8.
  • 17 Lee CY, Yen CC, Yen HJ, Shiau CY, Chao TC, Wu PK, et al. Outcomes of 50 patients with Ewing sarcoma family of tumors treated at a single institution in Taiwan. Medicine (Baltimore) 2016;95:e3830.
  • 18 Bentzen SM, Thames HD. Tumor volume and local control probability: Clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 1996;36:247-51.
  • 19 Donaldson SS, Torrey M, Link MP, Glicksman A, Gilula L, Laurie F, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: End results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:125-35.
  • 20 Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H, et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-14.
  • 21 Serlo JA, Helenius IJ, Sampo M, Vettenranta K, Saarinen-Pihkala UM, Kivivuori SM, et al. Ewing's sarcoma family of tumors in Finland during 1990-2009: A population-based study. Acta Oncol 2013;52:767-75.